1
|
Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z. Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease. Front Endocrinol (Lausanne) 2024; 15:1400891. [PMID: 38974573 PMCID: PMC11224516 DOI: 10.3389/fendo.2024.1400891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Accepted: 05/29/2024] [Indexed: 07/09/2024] Open
Abstract
Background Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD. Methods Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation. Results Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20-68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35-88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74-88.00). Conclusions SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.
Collapse
Affiliation(s)
- Yichao Wang
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Jiaye Liu
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yiqiao Fang
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Shengliang Zhou
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Xueting Liu
- Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Zhihui Li
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| |
Collapse
|
2
|
Cho-Fon C, Ngokwe ZB, Ines ON. A Rare Presentation of a Bi-Maxillary Brown Tumour due to Secondary Hyperparathyroidism. Case Rep Dent 2023; 2023:6180006. [PMID: 37021075 PMCID: PMC10070017 DOI: 10.1155/2023/6180006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/09/2023] [Accepted: 03/11/2023] [Indexed: 03/30/2023] Open
Abstract
Brown tumours are localized bone lesions, seen in patients with high parathyroid hormone levels. This can be due to primary hyperparathyroidism, which occurs more often in neoplasms of the parathyroid gland or due to secondary hyperparathyroidism more often seen as a result of renal impairment. Facial involvement is rare, with most reports focusing on long and axial bones. However, the mandibular bone is often the only bone affected. Here, we report a rare case of a bi-maxillary attainment of brown tumour in a patient with secondary hyperparathyroidism due to chronic kidney disease.
Collapse
|
3
|
Li X, Lin Q, Cui Y, Wang H, Wang P, Yang L, Ye Q, Zhang R, Zhu X. Glycine Acts Through Estrogen Receptor Alpha to Mediate Estrogen Receptor Signaling, Stimulating Osteogenesis and Attenuating Adipogenesis in Ovariectomized Rats. Mol Nutr Food Res 2022; 66:e2100857. [PMID: 35212448 DOI: 10.1002/mnfr.202100857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 11/14/2021] [Indexed: 11/08/2022]
Abstract
SCOPE Glycine is commonly used as an additive in bone health supplements, the activity and differentiation of bone mesenchymal stem cells (BMSCs) are essential to bone metabolism, but the effect of Glycine on bone metabolism and specific mechanism are not fully clarified. METHODS AND RESULTS The ovariectomized rats to evaluate the effects of Glycine on bone quality and quantity is constructed; then used an ER signaling inhibitor (ICI182780) and an ERα deficient BMSCs to explore how Glycine mediated ERα regulating the osteogenic and adipogenic differentiation of BMSCs; furthermore, an autodock analysis is used to assess the affinity of Glycine and ERα. The results show that Glycine significantly moderated bone mass and bone microstructure in ovariectomized rats; Glycine stimulates the osteogenic differentiation and attenuates the adipogenic differentiation in OVX rats and BMSCs, and these effects could be abolished by ICI 182780; further docking experiment showes that Glycine and ERα have a stronger affinity, and finally proves that the impact of Glycine could be blocked by ERα. CONCLUSION Glycine stimulates osteogenesis and attenuates adipogenesis in ovariectomized rats, which process may involve in ERα mediated ER signaling pathway.
Collapse
Affiliation(s)
- Xiaoyun Li
- Department of Traditional Chinese Pharmacology, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,Guangdong Provincial Key laboratory of Traditional Chinese Informatization, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Qing Lin
- College of Traditional Chinese medicine, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Yan Cui
- College of Traditional Chinese medicine, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Haoyu Wang
- College of Traditional Chinese medicine, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Panpan Wang
- Guangdong Provincial Key laboratory of Traditional Chinese Informatization, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,The First Affiliated hospital of Jinan University, 613 Huangpu Avenue West, Guangzhou, Guangdong, 510630, P. R. China.,Cancer research Institution, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Li Yang
- Department of Traditional Chinese Pharmacology, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,Guangdong Provincial Key laboratory of Traditional Chinese Informatization, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Qianyun Ye
- College of Traditional Chinese medicine, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Ronghua Zhang
- Department of Traditional Chinese Pharmacology, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,Guangdong Provincial Key laboratory of Traditional Chinese Informatization, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,Cancer research Institution, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China
| | - Xiaofeng Zhu
- Department of Traditional Chinese Pharmacology, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,Guangdong Provincial Key laboratory of Traditional Chinese Informatization, 601 Huangpu Avenue West, Guangzhou, Guangdong, 510632, P. R. China.,The First Affiliated hospital of Jinan University, 613 Huangpu Avenue West, Guangzhou, Guangdong, 510630, P. R. China
| |
Collapse
|
4
|
Abstract
Haemodialysis (HD) is the commonest form of kidney replacement therapy in the world, accounting for approximately 69% of all kidney replacement therapy and 89% of all dialysis. Over the last six decades since the inception of HD, dialysis technology and patient access to the therapy have advanced considerably, particularly in high-income countries. However, HD availability, accessibility, cost and outcomes vary widely across the world and, overall, the rates of impaired quality of life, morbidity and mortality are high. Cardiovascular disease affects more than two-thirds of people receiving HD, is the major cause of morbidity and accounts for almost 50% of mortality. In addition, patients on HD have high symptom loads and are often under considerable financial strain. Despite the many advances in HD technology and delivery systems that have been achieved since the treatment was first developed, poor outcomes among patients receiving HD remain a major public health concern. Understanding the epidemiology of HD outcomes, why they might vary across different populations and how they might be improved is therefore crucial, although this goal is hampered by the considerable heterogeneity in the monitoring and reporting of these outcomes across settings. This Review examines the epidemiology of haemodialysis outcomes — clinical, patient-reported and surrogate outcomes — across world regions and populations, including vulnerable individuals. The authors also discuss the current status of monitoring and reporting of haemodialysis outcomes and potential strategies for improvement. Nearly 4 million people in the world are living on kidney replacement therapy (KRT), and haemodialysis (HD) remains the commonest form of KRT, accounting for approximately 69% of all KRT and 89% of all dialysis. Dialysis technology and patient access to KRT have advanced substantially since the 1960s, particularly in high-income countries. However, HD availability, accessibility, cost and outcomes continue to vary widely across countries, particularly among disadvantaged populations (including Indigenous peoples, women and people at the extremes of age). Cardiovascular disease affects over two-thirds of people receiving HD, is the major cause of morbidity and accounts for almost 50% of mortality; mortality among patients on HD is significantly higher than that of their counterparts in the general population, and treated kidney failure has a higher mortality than many types of cancer. Patients on HD also experience high burdens of symptoms, poor quality of life and financial difficulties. Careful monitoring of the outcomes of patients on HD is essential to develop effective strategies for risk reduction. Outcome measures are highly variable across regions, countries, centres and segments of the population. Establishing kidney registries that collect a variety of clinical and patient-reported outcomes using harmonized definitions is therefore crucial. Evaluation of HD outcomes should include the impact on family and friends, and personal finances, and should examine inequities in disadvantaged populations, who comprise a large proportion of the HD population.
Collapse
|